UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Completed
Unique ID issued by UMIN UMIN000021758
Receipt No. R000025091
Scientific Title A prospective observational study about fatigue in patients with unresectable pancreatic cancer who receive nab-paclitaxel plus gemcitabine therapy
Date of disclosure of the study information 2016/04/04
Last modified on 2017/10/04

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title A prospective observational study about fatigue in patients with unresectable pancreatic cancer who receive nab-paclitaxel plus gemcitabine therapy
Acronym A observational study about fatigue in patients who receive nab-paclitaxel plus gemcitabine therapy
Scientific Title A prospective observational study about fatigue in patients with unresectable pancreatic cancer who receive nab-paclitaxel plus gemcitabine therapy
Scientific Title:Acronym A observational study about fatigue in patients who receive nab-paclitaxel plus gemcitabine therapy
Region
Japan

Condition
Condition Patients with unresectable pancreatic cancer
Classification by specialty
Hematology and clinical oncology Hepato-biliary-pancreatic surgery
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 We evaluate fatigue in patients with unresectable pancreatic cancer who receive nab-paclitaxel plus gemcitabine therapy using several scores.
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Evaluation of fatigue using FACIT-F (Functional Assessment of Chronic Illness Therapy-Fatigue) score untill eight weeks after stating chemotherapy.
Key secondary outcomes Evaluation of appetite loss using NRS(Numerical Rating Scale), peripheral neuropathy using PNQ(Patient Neurotoxicity Questionnaire), sensitive disorders using NRS, nutritional data, anemia using CTCAE criteria, accomplishment of chemotherapy schedule, usage rate of G-CSF, steroids etc., and overall survival.

Base
Study type Observational

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria 1)Patient with unresectable pancreatic cancer who receive nab-paclitaxel plus gemcitabine
2)Patient with pancreatic cancer stage UICC TNM classification III-IV
3)Estimated overall survival>3months
4)ECOG-PS 0 or 1
5)Main organs function test almost within normal range:
WBC>=3,500/mm3, <=12,000/mm3
Neutrophil>=1,500/mm3
Platelet>=100,000/mm3
Hemoglobin>=9.0g/dl
AST, ALT<=100IU/l
Total bilirubin<=2.0mg/dl,In biliary drainage cases<3.0mg/dl
Creatinine<=1.2mg/dl
6)Age>=20 years old
7)Outpatient clinic patient
8)Informed concent was obtained
Key exclusion criteria 1)Patients with severe co-morbidity such as heart failure, renal failure, or bowel obstruction.
2)Patients with pregnancy.
3)Patients with active cancer of other organs.
4)Patients with intorerable of oral medications.
5)Patients who is not suitable for undergoing the study safely.
Target sample size 10

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Hiroki Yamaue
Organization Wakayama Medical University
Division name Second Department of Surgery
Zip code
Address 811-1, Kimiidera, Wakayama
TEL 073-447-2300
Email yamaue-h@wakayama-med.ac.jp

Public contact
Name of contact person
1st name
Middle name
Last name Ken-ichi Okada
Organization Wakayama Medical University
Division name Second Department of Surgery
Zip code
Address 811-1, Kimiidera, Wakayama
TEL 073-441-0613
Homepage URL
Email okada@wakayama-med.ac.jp

Sponsor
Institute Wakayama Medical University
Institute
Department

Funding Source
Organization none
Organization
Division
Category of Funding Organization Other
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2016 Year 04 Month 04 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Completed
Date of protocol fixation
2016 Year 04 Month 03 Day
Date of IRB
Anticipated trial start date
2016 Year 04 Month 04 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information Study design: prospective observation study.
Method of recruiting: patientswho present outpatient clinic of Wakayama Medical University Hospital and eligible to this study.
Measurement item:
1. fatigue evaluated by NRS until 8 weeks after first administration
2. appetite loss evaluate by NRS until 8 weeks after first administration
3. peripheral neuropathy evaluated by PNQ until 8 weeks after first administration
4. sensory disturbance evaluated by NRS until 8 weeks after first administration
5. Nutritional status evaluated by albumin, prealbumin, and body weight until 8 weeks after first administration
6. anemia evaluated by CTCAE until 8 weeks after first administration
7. overall survival

Management information
Registered date
2016 Year 04 Month 03 Day
Last modified on
2017 Year 10 Month 04 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000025091

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.